ATNM Actinium Pharmaceuticals, Inc. (Delaware)
Legal ·
The case names Actinium and executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala and Sergio Giralt. Four derivative suits against directors and officers follow the same allegations.
We have not published a story on Actinium Pharmaceuticals, Inc. (Delaware) yet. When there is news, it will appear here.
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for solid tumors and hematologic malignancies. It takes a biology-driven approach to develop first-in-class radiopharmaceutical therapeutics built on tumor biology and radiochemistry. Its solid tumor candidate, ATNM-400, targets a novel antigen that does not target PSMA, and the company reports pre-clinical activity across metastatic castration-resistant prostate cancer, non-small cell lung cancer and breast cancer. Actimab-A is a CD33-targeted therapy that depletes myeloid derived suppressor cells and is being studied in multiple solid tumors in combination with immune checkpoint inhibitors. The company also develops Actimab-A as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute. Its two conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapies, are CD45-targeting. The company describes Actimab-A and Iomab-B as Phase 2/3 ready assets, and says Iomab-B has FDA alignment on a Phase 2/3 trial design in relapsed or refractory AML.
| Product or program | What it is | Stage |
|---|---|---|
| ATNM-400 | Radiotherapy against a novel non-PSMA antigen for prostate, lung and breast cancer | Pre-clinical activity demonstrated |
| Actimab-A | CD33-targeted therapy for solid tumors, AML and MDS | Phase 2/3 ready |
| Iomab-B | CD45-targeting conditioning agent for bone marrow transplant | Phase 2/3 ready; FDA alignment on trial design |
| Iomab-ACT | CD45-targeting conditioning agent for cell and gene therapies |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $90,000 | |
| Research and development | $21.1 million | $30.0 million |
| Net income (loss) | -$33.9 million | -$38.2 million |
| Cash from operations | -$24.6 million | -$33.1 million |
| Cash and equivalents | $48.0 million | $72.9 million |
Our latest story on this, dated Oct 15, 2026: "Actinium securities class action dismissed with prejudice; plaintiffs file appeal". The story links the filing or release it is based on. Read the story.
Actinium Pharmaceuticals, Inc. (Delaware) trades under the ticker ATNM on AMEX.
Actinium Pharmaceuticals, Inc. (Delaware) is listed on AMEX. Our directory also records these other listings: GETTEX:7AY1; LS:A2QA48; LSX:A2QA48.
The SEC Central Index Key (CIK) for Actinium Pharmaceuticals, Inc. (Delaware) is 1388320. Its filings are on SEC EDGAR.
31,441,436 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Actinium Pharmaceuticals, Inc. (Delaware) under United States.
Our directory classifies Actinium Pharmaceuticals, Inc. (Delaware) as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Actinium Pharmaceuticals, Inc. (Delaware) is US00507W2061.
aibio.space lists Actinium Pharmaceuticals, Inc. (Delaware) among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for solid tumors and hematologic malignancies. It takes a biology-driven approach to develop first-in-class radiopharmaceutical therapeutics built on tumor biology and radiochemistry.
ATNM-400: Radiotherapy against a novel non-PSMA antigen for prostate, lung and breast cancer Stage: Pre-clinical activity demonstrated.
Actimab-A: CD33-targeted therapy for solid tumors, AML and MDS Stage: Phase 2/3 ready.
$90,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Actinium Pharmaceuticals, Inc. (Delaware) reported a net loss of $33.9 million for the fiscal year ended Dec 31, 2025, and used $24.6 million of cash in operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio